Clear Path For AstraZeneca’s Roxadustat After Reassuring Safety Data

Filing Expected Before Year-End

 
• By Andrew McConaghie

Strong results in non-dialysis patients are a particular boost for AZ and its partner, Fibrogen.

AZ_China
AstraZeneca's operations in China, where roxodustat is already approved • Source: AstraZeneca

More from Clinical Trials

More from R&D